682804-98-4 Usage
Uses
Used in Pharmaceutical Research:
4-FLUORO-2-METHOXYCINNAMIC ACID is used as a research compound for its anti-inflammatory and anticancer properties. It is being studied for its potential to contribute to the development of new drugs and therapies that can address these health concerns.
Used in Organic Synthesis:
In the field of organic synthesis, 4-FLUORO-2-METHOXYCINNAMIC ACID serves as a building block for the synthesis of novel chemical compounds. Its unique structure allows it to be a valuable component in creating various industrial and medical applications.
Used in Drug Development:
4-FLUORO-2-METHOXYCINNAMIC ACID is also utilized in drug development, where its potential biological activities are harnessed to formulate new treatments for different diseases, particularly those with inflammatory and cancerous conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 682804-98-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,2,8,0 and 4 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 682804-98:
(8*6)+(7*8)+(6*2)+(5*8)+(4*0)+(3*4)+(2*9)+(1*8)=194
194 % 10 = 4
So 682804-98-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H9FO3/c1-14-9-6-8(11)4-2-7(9)3-5-10(12)13/h2-6H,1H3,(H,12,13)/b5-3+
682804-98-4Relevant academic research and scientific papers
Hepatitis C virus inhibitors
-
Page/Page column 57, (2017/01/23)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C Virus Inhibitors
-
Paragraph 0291; 0292, (2015/11/02)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C Virus Inhibitors
-
Page/Page column, (2013/05/21)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
